Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Screening Strategies for Silent Myocardial Ischemia in Individuals With Diabetes Without Known Coronary Artery Disease: Systematic Review and Meta-Analysis.

Created on 05 Oct 2026

Authors

Vanessa Del Carmen Romero Martínez, Juan Pablo Tobón Cuenca, Paula Alejandra Longas García, Luis Eduardo Salazar Moreno, Gloria Ibis Tirado Romero

Published in

Clinical cardiology. Volume 49. Issue 10. Pages e70470.

Abstract

Diabetes mellitus markedly increases atherosclerotic cardiovascular risk, and coronary artery disease remains a leading cause of morbidity and mortality. Silent myocardial ischemia (SMI) is clinically relevant in diabetes because autonomic dysfunction and altered pain perception may attenuate typical ischemic symptoms; however, the clinical benefit of routine screening in asymptomatic individuals without known coronary artery disease (CAD) remains uncertain.
To evaluate whether systematic screening for silent myocardial ischemia or occult CAD in asymptomatic adults with diabetes and no known CAD improves major cardiovascular outcomes.
We performed a systematic review of studies published from January 1, 2000 through March 31, 2025. The primary effectiveness synthesis included randomized trials comparing systematic screening with no systematic screening or usual care. Primary outcomes were major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality; secondary outcomes included detection yield, downstream testing or revascularization, and reported screening-related harms. Compatible study-level hazard ratios (HRs) and risk ratios (RRs) were synthesized on the log scale using random-effects inverse-variance meta-analysis, with heterogeneity and sensitivity analyses prespecified. The review was not prospectively registered.
Five RCTs (n = 3315; DIAD, DYNAMIT, FACTOR-64, DADDY-D, and the pilot trial by Faglia et al.) met the eligibility criteria. Screening did not significantly reduce major cardiovascular outcomes in the four trials included in the quantitative synthesis (pooled HR/RR 0.76; 95% CI 0.48-1.19). DYNAMIT was synthesized narratively because its published primary composite was not directly harmonizable with the pooled endpoint. Reporting of false-positive results and procedure-related harms was incomplete and heterogeneous.
In asymptomatic adults with diabetes and no known CAD, routine screening detects occult ischemia or atherosclerosis but has not demonstrated a reduction in MACE or mortality compared with the trial-era usual-care or protocol-defined medical-management strategies studied. These findings do not support routine population-wide screening; selective testing is most defensible when the result is expected to change management.

PMID:
42831381
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 19
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement